Blockbuster weight-loss drugs are transforming the way we treat obesity. But while costly injectable versions remain out of reach for many, newly approved tablet forms are expected to significantly boost access and demand. However, a new study from Adelaide University, appearing in the Journal of Controlled Release, turns a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological effects for the gut and beyond.
This article was originally published on MedicalXpress.com
